NCARDIA

Company Overview

Ncardia is a human iPSC technology company operating throughout Europe and North America. Ncardia’s goal is to be the trusted partner for biopharmaceutical companies utilizing hiPSCs in drug discovery and cell therapy. In August 2017, Ncardia was formed by merging two private stem cell technology firms, Axiogenesis AG and Pluriomics BV. Pluriomics was established in 2011 by Stefan Braam and Herman Spolders, together with the scientific founders Professor Dr. Mummery and Professor Dr. Passier.

Ncardia is a leader in contract research, manufacture, and development of human induced pluripotent stem cell-based solutions. The company’s capabilities include disease modeling, assay development, large-scale iPSC manufacturing, and iPSC-based screening. Ncardia provides a universal strategy and vertically integrated iPSC platform for the design and controlled production of cell models and associated assays. The platform comprises multiple interconnecting technologies and services to accommodate projects for various therapeutic modalities at any stage of development.

The company’s cardiac products encompass hiPSC-derived cardiomyocytes and a broad neural cell portfolio. Building on its expertise, Ncardia also provides cardiovascular and neuronal services from disease modeling to drug efficacy screening and cardiac safety assessment. The only iPSC-based cell therapy process development and manufacturing system designed specifically to enable large-scale allogeneic cell therapy production was introduced by Ncardia in April 2022 with the Cellistic product.

In June 2023, in the field of gene therapies, an amazing milestone was reached after years of devoted research. The Food and Drug Administration (FDA) granted Sarepta Therapeutics fast clearance for its groundbreaking medication that targets Duchenne muscular dystrophy (DMD). This incredible accomplishment represents not only the first-ever preliminary approval of a gene therapy but also a major step in the field of gene therapy development.

Ncardia and BlueRock Therapeutics announced in January 2020 that they reached an agreement regarding process development technologies for the production of cardiomyocytes produced from induced pluripotent stem cells (iPSCs). In order to produce iPSC-derived cardiomyocytes for therapeutic use, Bluerock was granted access to Ncardia’s large-scale production procedures and intellectual property under the conditions of the agreement.

Ncardia’s DiscoverHIT drug screening platform was launched in February 2019. To expedite the development of better drugs for patients, the new service gives researchers access to human disease-relevant biology early in the drug discovery process.

Company's Business Segments

• iPSC-based Drug Discovery Platform : This segment helps its customers Mimic Drug Interactions with the human body from hit identification to lead optimization.